Clinical trial · no report yet · Phase 2
IZALCO
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT05704049 ↗
- Active not recruiting
- Sanofi
- 29 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 15 | |
| Podcasts | 12 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Phase 2, Open Label Study Evaluating Subcutaneous Administration of Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Isatuximab; Carfilzomib; Dexamethasone; Dexamethasone IV; Montelukast; Acetaminophen; Diphenhydramine; Methylprednisolone
- Arms
- Cohort 1: manual administration · Experimental
- Part 1 Cohort 2: manual administration · Experimental
- Part 2 Cohort 3 Randomized Cohort: OBDS to manual · Experimental
- Part 2 Cohort 3 Randomized Cohort: Manual to OBDS · Experimental
- Part 3 Cohort 4 Randomized Cohort: OBDS to manual · Experimental
- Part 3 Cohort 4: Randomized Cohort: manual to OBDS · Experimental
- Part 3 Cohort 5 Randomized Cohort: OBDS to manual administration in Chinese participants · Experimental
- Part 3 Cohort 5 Randomized Cohort: manual to OBDS administration in Chinese participants · Experimental
- Enrollment
- 118
- Primary outcomes
- Overall response rate (ORR) - Cohorts 1 to 3
- Maximum observed concentration (Cmax) over Cycle 1- Cohorts 4 to 5
- Cumulative area under the curve over the first 4 weeks (AUC4weeks) of isatuximab treatment- Cohorts 4 to 5
- Sponsor
- Sanofi
- Start
- Apr 5, 2023
- Primary completion
- Dec 22, 2025
- Results posted
- No
- Registry record
- NCT05704049 · updated Dec 29, 2025
Publications
linked from the registry- Parmar G, Capra M, Seguro F, Hungria V, Dimopoulos MA, Delimpasi S, Minarik J, Spicka I, Pour L, Marques H, Esteves G, Sunami K, Yuda J, Hajek R, Mihalyova J, Soufflet C, Yu D, Benlhassan K, Koch V, Comerford E, Cordero P, Suzan F, Quach H. Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO. Blood Cancer J. 2025 Dec 27;16(1):16. doi: 10.1038/s41408-025-01436-0. PubMed 41455697